<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362347">
  <stage>Registered</stage>
  <submitdate>16/04/2012</submitdate>
  <approvaldate>18/04/2012</approvaldate>
  <actrnumber>ACTRN12612000441819</actrnumber>
  <trial_identification>
    <studytitle>Variable Concentrations of Oxygen in Chronic Obstructive Pulmonary Disease</studytitle>
    <scientifictitle>Response of Patients with Chronic Obstructive Pulmonary Disease to Variable Concentrations of Oxygen, as Measured by Carbon Dioxide</scientifictitle>
    <utrn>U1111-1130-0109</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oxygen administered to all participants at 28, 35 and 50%, each for 30 minutes with a 30 minute washout period following, via a venturi mask system.</interventions>
    <comparator>Oxygen administered at 21% (room air concentration) for 30 minutes with a 30 minute washout period following, via a venturi mask system.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>Countinuously measured via the TOSCA, and specifically recorded at 10 minute intervals, during the intervention and washout periods.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Transcutaneous oxygen level, adjusted for baseline, as recorded on the TOSCA.</outcome>
      <timepoint>Continuously over the time course of the intervention and washout periods.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of baseline transcutaneous carbon dioxide, as recoded via the TOSCA, on outcome.</outcome>
      <timepoint>Value from baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate, adjusted for baseline, as recorded on the TOSCA.</outcome>
      <timepoint>10 minute intervals during the intervention and washout periods.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory rate, adjusted for baseline, counted by investigator.</outcome>
      <timepoint>10 minute intervals during the intervention and washout periods.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of chronic obstructive pulmonary disease with oxygen induced elevation in transcutaneous carbon dioxide levels of greater than or equal to 4mmHg.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>An intercurrent chest infection
FEV1:FVC &gt;0.7
Baseline transcutaneous carbon dioxide of greater than 60mmHg
Diagnosis of a disease causing restriction to chest wall expansion (neuromuscular disease or chest wall dysfunction)
Obesity (body mass index greater than or equal to 40)
Any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following explaination of the trial and consent, participants will be assessed for eligibility. If eligible, participants will be randomised to the order of interventions (21%, 28%, 35% or 50% oxygen). Allocation will be concealed using sealed opaque envelopes, which will only be opened once eligibilty has been confirmed.</concealment>
    <sequence>Computer</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>26/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Janine Pilcher</primarysponsorname>
    <primarysponsoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Medical Research Institute of New Zealand</fundingname>
      <fundingaddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Richard Beasley</sponsorname>
      <sponsoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Kyle Perrin</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Pip Shirtcliffe</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mitesh Patel</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Irene Braithwaite</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mathew Williams</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mark Weatherall</othercollaboratorname>
      <othercollaboratoraddress>Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It is well established that oxygen therapy can increase carbon dioxide in patients with chronic obstructive pulmonary disease. However, the dose-response relationship is unknown, in particular whether this effect occurs above a certain oxygen concentration threshold. 

This needs to be explored to ensure guidelines appropriately recommend oxygen prescription to minimise the incidence of hypercapnia (high carbon dioxide levels). 

We plan to explore this with a randomised controlled four way cross over clinical trial of varying concentrations of oxygen therapy in chronic obstructive pulmonary disease patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee: Northern Y</ethicname>
      <ethicaddress>130 Grantham St, Hamilton 3204</ethicaddress>
      <ethicapprovaldate>28/03/2012</ethicapprovaldate>
      <hrec>NTY/12/01/009</hrec>
      <ethicsubmitdate>12/01/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>